SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Manco Antonio)
 

Sökning: WFRF:(Manco Antonio) > (2024) > International Diabe...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005903naa a2200529 4500
001oai:lup.lub.lu.se:8c436475-3ff1-41c8-a073-6b257f4d5a86
003SwePub
008240402s2024 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/8c436475-3ff1-41c8-a073-6b257f4d5a862 URI
0247 a https://doi.org/10.1016/j.diabres.2024.1115892 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Bergman, Michaelu NYU Grossman School of Medicine4 aut
2451 0a International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes
264 1c 2024
520 a Many individuals with intermediate hyperglycaemia (IH), including impaired fasting glycaemia (IFG) and impaired glucose tolerance (IGT), as presently defined, will progress to type 2 diabetes (T2D). There is confirmatory evidence that T2D can be prevented by lifestyle modification and/or medications, in people with IGT diagnosed by 2-h plasma glucose (PG) during a 75-gram oral glucose tolerance test (OGTT). Over the last 40 years, a wealth of epidemiological data has confirmed the superior value of 1-h plasma glucose (PG) over fasting PG (FPG), glycated haemoglobin (HbA1c) and 2-h PG in populations of different ethnicity, sex and age in predicting diabetes and associated complications including death. Given the relentlessly rising prevalence of diabetes, a more sensitive, practical method is needed to detect people with IH and T2D for early prevention or treatment in the often lengthy trajectory to T2D and its complications. The International Diabetes Federation (IDF) Position Statement reviews findings that the 1-h post-load PG ≥ 155 mg/dL (8.6 mmol/L) in people with normal glucose tolerance (NGT) during an OGTT is highly predictive for detecting progression to T2D, micro- and macrovascular complications, obstructive sleep apnoea, cystic fibrosis-related diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, and mortality in individuals with risk factors. The 1-h PG of 209 mg/dL (11.6 mmol/L) is also diagnostic of T2D. Importantly, the 1-h PG cut points for diagnosing IH and T2D can be detected earlier than the recommended 2-h PG thresholds. Taken together, the 1-h PG provides an opportunity to avoid misclassification of glycaemic status if FPG or HbA1c alone are used. The 1-h PG also allows early detection of high-risk people for intervention to prevent progression to T2D which will benefit the sizeable and growing population of individuals at increased risk of T2D. Using a 1-h OGTT, subsequent to screening with a non-laboratory diabetes risk tool, and intervening early will favourably impact the global diabetes epidemic. Health services should consider developing a policy for screening for IH based on local human and technical resources. People with a 1-h PG ≥ 155 mg/dL (8.6 mmol/L) are considered to have IH and should be prescribed lifestyle intervention and referred to a diabetes prevention program. People with a 1-h PG ≥ 209 mg/dL (11.6 mmol/L) are considered to have T2D and should have a repeat test to confirm the diagnosis of T2D and then referred for further evaluation and treatment. The substantive data presented in the Position Statement provides strong evidence for redefining current diagnostic criteria for IH and T2D by adding the 1-h PG.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
7001 a Manco, Melaniau Bambino Gesù Children’s Hospital4 aut
7001 a Satman, Ilhan4 aut
7001 a Chan, Julianau Chinese University of Hong Kong4 aut
7001 a Inês Schmidt, Mariau Hospital de Clinicas de Porto Alegre4 aut
7001 a Sesti, Giorgiou Sapienza University of Rome4 aut
7001 a Vanessa Fiorentino, Teresau University Magna Graecia4 aut
7001 a Abdul-Ghani, Muhammadu University of Texas Health Science Centre4 aut
7001 a Jagannathan, Ramu Emory University Rollins School of Public Health4 aut
7001 a Kumar Thyparambil Aravindakshan, Pramodu Madras Diabetes Research Foundation4 aut
7001 a Gabriel, Rafaelu Carlos III Health Institute4 aut
7001 a Mohan, Viswanathanu Madras Diabetes Research Foundation4 aut
7001 a Buysschaert, Martinu Saint-Luc University Hospital4 aut
7001 a Bennakhi, Abdullah4 aut
7001 a Pascal Kengne, Andreu South African Medical Research Council4 aut
7001 a Dorcely, Brendau NYU Grossman School of Medicine4 aut
7001 a Nilsson, Peter M.u Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)medf-pni
7001 a Tuomi, Tiinamaijau Folkhälsan Research Center,Helsinki University Central Hospital4 aut0 (Swepub:lu)ti8736tu
7001 a Battelino, Tadeju University of Ljubljana4 aut
7001 a Hussain, Akhtaru Federal University of Ceará,Nord University4 aut
7001 a Ceriello, Antoniou IRCCS Multimedica4 aut
7001 a Tuomilehto, Jaakkou King Abdulaziz University,University of Helsinki,Finnish National Institute for Health and Welfare4 aut
7102 a NYU Grossman School of Medicineb Bambino Gesù Children’s Hospital4 org
7730 t Diabetes Research and Clinical Practiceg 209q 209x 0168-8227
8564 u http://dx.doi.org/10.1016/j.diabres.2024.111589y FULLTEXT
8564 8u https://lup.lub.lu.se/record/8c436475-3ff1-41c8-a073-6b257f4d5a86
8564 8u https://doi.org/10.1016/j.diabres.2024.111589

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy